Belgian pharma veteran Jean Stéphenne, the chairman of the German vaccine developer CureVac, experienced the global rollercoaster that set corona in motion from day one. “I don’t believe in lifelong protection.”
–
Of all Belgian vaccine experts of international renown, 71-year-old Jean Stéphenne has by far the most years of service. He played a key role in the development of the vaccine division of the British GlaxoSmithKline in Rixensart, Walloon Brabant, where thousands of people now work.
–
Since he stepped down as CEO in 2012 – with a word of thanks from Bill Gates at his farewell party – Stéphenne has by no means rested on his laurels. In Wallonia, he is an investor and chairman of many biotech companies. In April he competed in the race for a corona vaccine as chairman of the German CureVac.
–
Because Stéphenne belongs to a high-risk group due to his age and was recovering from surgery just before the lockdown, he is extra careful. “When I see my grandchildren, we wear a mouth mask and meet outside as much as possible,” he says. ‘I shop once every two weeks and work mainly via video meetings. I don’t go to restaurants or museums. (laughs) I run a greater risk, even though US President Donald Trump says you shouldn’t be afraid of Covid-19. ‘
–
What did you think of the verdict?
Jean Stephenne: ‘A big mistake. He has easy talking. He enjoys the best care and was given a cocktail of medicines, including some experimental treatments. ‘
–
You take your precautions, but remain very active. Is this the busiest period of your career?
Stephenne: ‘Nope. At GSK I worked seven days a week, 14 to 15 hours a day. Now I work three to four days a week. I also do not have an executive role at CureVac, but use it to map out the strategy. ‘
–
This strategy focuses on mRNA technology, a discipline that is on the rise in the medical world for the development of cancer treatments and vaccines, among other things. In the case of the corona vaccine, mRNA (messenger RNA), a piece of hereditary material, is injected. This instructs cells to make a specific protein that is characteristic of the virus. The body sees the protein as an intruder, enters the fight and in this way prepares itself for another, real virus attack.
–
The three companies at the forefront of an mRNA vaccine, CureVac, Biontech and Moderna, are listed on the American technology exchange Nasdaq. Their joint stock market value amounts to around USD 60 billion.
–
There will be enough vaccines to vaccinate every European next year. But everyone must want that too.